Drug-Diagnostic Co-Development in Cancer

  title={Drug-Diagnostic Co-Development in Cancer},
  author={Henrik Winther and Jan Tr{\o}st J{\o}rgensen},
  journal={Pharmaceutical Medicine},
Within oncology, companion diagnostics are considered to be of important value as the efficacy rates of anticancer pharmacotherapy in many cases remain low. Both the costs and the consequences of treatment failure are significant. Drug-diagnostic combinations have been known for several decades within oncology and the preselection of patients based on the differences in their biology was practiced as early as the 1970s. In relation to the development of the first companion diagnostic (for the… 

Companion Diagnostics in Oncology - Current Status and Future Aspects

New ways should be developed to demonstrate the clinical utility of drug-diagnostic combinations to benefit from the increasing knowledge provided by molecular oncology, and is likely to include a number of ethical, regulatory and practical challenges.

A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer

HercepTest™ was the first companion diagnostic ever approved by the FDA, and more than 20 years of use has documented its clinical impact.

Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity.

It is asserted that development of drugs and CDx targeted towards molecular and centrosomal aberrations that occur more frequently in AAs could yield next generation precision medicine tools better informed and inspired by, and more finely attuned to the unique tumor biology of AAs.

The HER2 CISH pharmDx™ Kit in the assessment of breast cancer patients for anti-HER2 treatment

The US FDA has recently approved the Her2 CISH pharmDx™ Kit, which is characterized by employing a chromogenic visualization system that allows quantification of the HER2 gene and centromere 17 reference signals by relatively low-magnification brightfield microscopy.

Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges

To fully realize the benefits of PM for healthcare systems and patients, regulatory, intellectual property, and reimbursement challenges need to be addressed in lock step with scientific advances.

In Vitro Effect of Pomalidomide on Bone Marrow Mononuclear Cells From Multiple Myeloma Patients

Pomalidomide has the potential to increase IL2 production within bone marrow mononuclear cells and consequently make changes in the immune response, which requires further studies for more clarifications.

A New Look at the Corporate Capability of Personalized Medicine Development in the Pharmaceutical Industry

A model develops a model to illustrate the corporate capability of personalized medicine development (PMD capability) in the pharmaceutical industry and finds that the critical path to contribute to PMD capability runs from NPD capability via External CoDxD capability rather than via Internal CoDXD capability.

Interpretation of laboratory tests results in cancer patients

Basic laboratory tests are sedimentation rate, blood count, biochemistry, coagulation parameters and tumor markers, which indicate that there has been regression or progression of tumor growth, spreading of metastases and, therefore, prediction of survival.



Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer.

Patients with a high probability to benefit from targeted therapies, such as antiestrogens, human epidermal growth factor receptor 2 inhibitors, and topoisomerase inhibitors are identified based on a biopsy from the tumor.

Opportunities and challenges in the development of targeted therapies.

It is imperative that targeted therapies are devoid of toxicities secondary to the ubiquitous nature of the target, and the authors must improve the understanding of interactions that provide specificity of signaling under physiologic conditions.

The role of companion diagnostics in the development and use of mutation-targeted cancer therapies

Development of companion diagnostic tests for this identification of patients most likely to benefit from therapies based on agents that specifically target the products of the genes that are mutated in cancer cells is proceeding.

Personalized cancer therapy--the key to the future.

Although the global patterns of chemotherapy use varies enormously, the overall outcomes are similar and step changes in technology may make it possible to use serumbased approaches, such as proteomics, to provide adequate information on tumor characteristics without recourse to tissue access.

Targeted HER2 Treatment in Advanced Gastric Cancer

It is expected that the encouraging results from the ToGA trial will have an immediate impact on the management of patients and that routine HER2 testing of patients with advanced gastric cancer will be initiated within a relatively short period of time.

The new era of personalized medicine: 10 years later.

There are obstacles to be overcome with regard to the implementation of personalized medicine, and besides scientific and economic issues, it will be a challenge to address other aspects, such as regulatory requirements, reimbursement, education and logistics.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ra did benefit fromcetuxIMab.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.

Treatment options in metastatic renal carcinoma: an embarrassment of riches.

  • N. Vogelzang
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
The first full report of a major advance in the treatment of metastatic renal cell carcinoma (RCC) is contained, showing that 45 of 53 patients treated after failure of first-line cytokine therapy had some degree of minor or major regression of disease accompanied by a median survival of 16.4 months.

Randomized Phase III Clinical Trial Designs for Targeted Agents

This article investigates the performance of several phase III clinical trial designs, both for testing the overall efficacy of a targeted agent and for testing its efficacy in a subgroup of patients with a tumor marker present.